[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100631406":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":24,"locations":10,"responsibleParty":30,"collaborators":32,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":40,"acronym":41,"eligibilityCriteria":42,"healthyVolunteers":38,"sex":43,"minAge":44,"maxAge":10,"enrollmentInfo":45,"targetDuration":10,"studyType":48,"phases":10,"briefSummary":49,"conditions":50,"keywords":53,"overallStatus":57,"whyStopped":10,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":10},{"fullName":5,"class":6},"Luxembourg Institute of Health","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"CRC",null,"Participants are included while scheduled for biopsy or surgery of their colorectal cancer.",[13],"Other: Personalized Functional Profiling",{"label":15,"type":10,"description":16,"interventionNames":17},"PDAC","Participants are included while scheduled for biopsy or surgery of their cancer.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"OTHER","Personalized Functional Profiling","This is an observational study where biological samples are collected to provide Personalized Functional Profiling, an integrated strategy that combines genomic analysis with direct drug response assessments using patient-derived spheroids\u002Forganoids (PDSOs)",[9,15],[25],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Yong Jun Kwon, phD","CONTACT","+352 26970-288","yong-jun.kwon@lih.lu",{"type":31,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[33],{"name":34,"class":35},"Hopitaux Robert Schuman","UNKNOWN","100631406","exploratory-clinical-evaluation-of-personalized-functional-profiling-in-gi-tumors-predicting-drug-response-in-crc-and-pdac-100631406",false,"NCT07500259","Exploratory Clinical Evaluation of Personalized Functional Profiling in GI Tumors: Predicting Drug Response in CRC and PDAC","COLOPan","Inclusion Criteria:\n\n* Signed informed consent form\n* ≥ 18 years of age\n* Willing and able to comply with the protocol for the duration of the study, including data and sample collection\n* Patient scheduled for surgery or biopsy (primary tumour or metastasis) PDAC\n\nExclusion Criteria:\n\n* Female patient, pregnant, planning a pregnancy or breastfeeding.\n* Known active Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection.\n* Patient unable to understand and provide informed consent and has no family member representing him\u002Fher.\n* Patients with any other life-threatening illness, significant organ dysfunction or any clinically relevant conditions that, according to the hospital physician, could compromise the patient's safety.","ALL","18 Years",{"count":46,"type":47},188,"ESTIMATED","OBSERVATIONAL","The ColoPan study evaluates the scientific validity, reproducibility, and predictive performance of the Personalised Functional Profiling (PFP) platform in colorectal cancer and pancreatic ductal adenocarcinoma patients. It combines genomic sequencing with in vitro functional drug testing using patient-derived spheroids\u002Forganoids.",[51,52],"Colorectal Cancer","PDAC - Pancreatic Ductal Adenocarcinoma",[54,55,56],"Drug profiling","Precision medicine","clinical validation","NOT_YET_RECRUITING","2026-06-18",{"date":60,"type":61},"2026-06-23","ACTUAL",{"date":63,"type":47},"2026-07-01",{"date":65,"type":47},"2034-11-01",{"name":5,"class":6}]